IGF2 and cancer: Both, IGF2 and its receptor IGF1R constitute desirable therapeutic targets; mainly due to these evidences showing that targeting either IGF2 or its receptor IGF1R, blocks cancer progression and displays significant antitumor activity (Xing et al., 2021).